key: cord-1008637-c3w2y6ab
authors: Omotuyi, I. O.; Olubiyi, O.; Nash, O.; Afolabi, E.O.; Oyinloye, B.E.; Fatumo, S.; Femi-Oyewo, M. N.; Bogoro, S.E.
title: SARS-CoV-2 Omicron Spike Glycoprotein Receptor Binding Domain Exhibits Super-Binder Ability with ACE2 but not Convalescent Monoclonal Antibody
date: 2021-12-09
journal: bioRxiv
DOI: 10.1101/2021.12.09.471885
sha: c12e76e1fe0df52f62312f51304e703bbc97bc12
doc_id: 1008637
cord_uid: c3w2y6ab

Background SARS-CoV-2, the causative virus for COVID-19 has now super-mutated into the Omicron (Om) variant. On its spike glycoprotein alone, more than 30 substitutions have been characterized with 15 within the receptor binding domain (RBD); It therefore calls to question the transmissibility and antibody escapability of Omicron. This study was setup to investigate the Omicron RBD’s interaction with ACE2 (host receptor) and a SARS-CoV-2 neutralizing monoclonal antibody (mAb). Methods In-silico mutagenesis was used to generate the Om-RBD in complex with ACE2 or mAb from the wildtype. All-atom molecular dynamics (MD) simulation trajectories were analyzed for interaction. Results MD trajectories showed that Omicron RBD has evolved into an efficient ACE2 binder, via pi-pi (Om-RBD-Y501/ACE2-Y41) and salt-bridge (Om-RBD-K493/ACE2-Y41) interactions. Conversely, in binding mAb, it has become less efficient (Center of mass distance of RBD from mAb complex, wildtype ≈ 30 Å, Omicron ≈ 41 Å). Disruption of Om-RBD/mAb complex resulted from loose interaction between Om-RBD and the light chain complementarity-determining region residues. Conclusions Omicron is expected to be better transmissible and less efficiently interacting with neutralizing convalescent mAbs. General significance Our results elucidate the mechanisms for higher transmissibility in Omicron variant.

COVID-19 (coronavirus disease 2019) is caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) (Zhou et al. 2020) . SARS-CoV-2 tropism is initiated when its spike (S) glycoprotein binds to the host angiotensin-converting enzyme 2 (ACE2) and its partner transmembrane serine protease 2 (TMPRSS2) (32142651) serving as door-way to cellular entry. In addition to its role as the receptor (Wrapp et al. , 2020) , the S protein is also the key targets for several antibodies currently in use as treatment options for COVID-19; especially the receptor binding domain (RBD) (Zhou et al. , 2020) .

Notably, the antibodies generated by the Pfizer-BioNTech mRNA-BNT162b2, Moderna mRNA-1273 ultimately targets SARS-CoV2 spike glycoprotein (Fig. 1a, b-ii) at the receptorbinding domain (RBD, Fig. 1b, i-ii) ) while Astra-Zeneca-ChAdOx1-S and Janssen-Ad26.COV2.S were primarily designed to express SARS-CoV-2 spike protein as immunogen (Mascellino et al. , 2021) . Curiously, many convalescent monoclonal antibodies (mAbs) bind at the ACE2 site on the RBD (Bertoglio et al. , 2021) . It is therefore not surprising that as SARS-CoV-2 variants with mutations in the RBD begin to emerge (Omotuyi et al. , 2020) , so is concern over transmissibility and antibody escape (Mascellino et al., 2021) . Variants whose RBD mutations eventually resulted in worse clinical outcomes include: B. (Gao et al. , 2021) . Intriguingly most S protein substitutions (N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, Fig. 1c ) occur at the ACE2binding site of the RBD (Fig. 1d) . indicating that Omicron, but not the wildtype RBD has better ACE2 binding capacity.

Whilst it is to be noted that previous reports identified T478K, and N501Y substitutions are associated with increased ACE2 binding (Kim et al. , 2021) , in Omicron RBD, S496 resides within hydrogen-bond distance (≈ 3.5 Å) from ε -amino group of ACE2-K353 (Fig. 1f, i) , which is absent in Wildtype (G496, distance > 4.5 Å, Fig. 1f, ii) . Omicron K493 also evolved salt-bridge interaction with ACE2 D38 (distance ≈ 2.5-4.5 Å) as opposed to Q493 which fails to form hydrogen bond (distance > 6.0 Å, Fig. 1f, ii) . Further investigation showed that G496 (wildtype) allowed ACE2-K353/D38 salt-bridge interaction rather than engaging RBD (data not shown), thus, further weakening ACE2 binding in the wildtype.

We further elucidate that the stabilizing effect of N501Y mutation on ACE2 occurs through ACE2-K353 interaction (Fig. 1g, i) . Here, the measurement of the inter-atomic distance between the phenolic side chains of Y501 (RBD) and Y41 (ACE2) indicated a possible pi-pi interaction (distance < 6.0 Å, Fig. 1g, ii) ; a feature non-existent in wildtype (N501, distance > 6.9 Å, Fig. 1g, ii) . Y501/41 stacking spatially locks Y501 in place allowing cation-pi interaction (Fig. 1g, ii) with K353 (ACE2). A representation of the difference in the strengths of ACE2 interaction offered by wildtype (Fig. 1h, upper plane) and Omicron (Fig. 1h, lower plane) RBDs were also projected using a weighted network representation, with Omicron RBD residues displaying stronger network interaction within the substitution clusters.

Without a doubt, Omicron S protein RBD exhibits super-binder ability with ACE2 with resulting higher transmissibility potentials.

Next, we sought to understand how the Omicron RBD substitutions affect mAb binding, protein-protein docking and scoring with several available antibodies was initially performed.

A cursory look suggests that Omicron binding is associated with improved binding scores (Supplementary Table 1 Fig. 2a, ii) , and we showed that the antigen-binding fragments (Fab, residues 1-108 (heavy chain), residues 1-106 (light chain), Fig. 2a, iii) , for the first 30 ns was ≈ 3 Å less compact in binding Omicron RDB in comparison with the wildtype (Fig. 2a, iv) , This result suggest that local events at the RBD-Fab interface is responsible for the difference in mAb binding. Therefore, we further investigated the roles of each chain as most of the mutations cluster at the VLCDR binding interface (Fig. 2b, i) . A population plot of the COM distance between the mAb-light chain and RBD strongly suggest that Omicron RBD binds beyond sub-optimal distance (distance > 50 Å, Fig. 2b, ii) in comparison with the wildtype (distance < 47 Å) and surprisingly a similar pattern was observed in the heavy chain (Wildtype ≈ 37.5 Å vs. Omicron ≈ 38.5 Å, Fig. 2b, iii) .

Finally, specific mAb residues which account for the sub-optimal binding were identified.

Loss of interaction between S25/T28 (heavy chain CDRs) and T478K and S477N respectively (Fig. 2c, i, right and left panels) partially explain the loose binding with Omicron RBD and time-evolved dynamics setup for to monitor the interaction between clustered RBD substitutions (K417N, N440K, Q493R, G496S, Q498R, N501Y, and Y505H) and the VLCDR loop residues (Fig. 2d, i,) . The 2 Å separation of VLCDR loop residues from Omicron RBD for the first 20 ns of simulation (reconverged afterwards) is consistent with a previous studies where N501Y and K417N were associated with detached RBD from mAb light chain CDR1 loop (Dejnirattisai et al. , 2021) . These results suggest strongly that Omicron RBD is ACE2 super binder but damped convalescent mAb binder (Fig. 2e) . 

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Antibody evasion by the P.1 strain of SARS-CoV-2

Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert

Differential Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern. bioRxiv

CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety

Atomistic simulation reveals structural mechanisms underlying D614G spike glycoproteinenhanced fitness in SARS-COV-2

SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Coronavirus disease 2019 (COVID-19): a clinical update